Education
About Us
Working with TipRanks
Follow Us
Theriva Biologics (TOVX)
:TOVX
TOVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.03 - $12.28
Previous CloseN/A
Volume37.66K
Average Volume (3M)28.83K
Market Cap
$3.06M
Enterprise Value-$13.10M
Total Cash (Recent Filing)$11.61M
Total Debt (Recent Filing)$1.47M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
May 13, 2025EPS Estimate
-4.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-26.66
Shares Outstanding2,782,449
10 Day Avg. Volume17,103
30 Day Avg. Volume28,826
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap-4.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.67
Forecast
1Y Price Target
$6.00Price Target Upside435.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Theriva Biologics News
PremiumCompany Announcements
Theriva Biologics Reports Positive VIRAGE Phase 2b Results
PremiumCompany Announcements
Theriva Biologics Reports 2024 Financial Results and Progress
PremiumCompany Announcements
Theriva Biologics Advances VCN-01 with FDA Guidance
PremiumCompany Announcements
Theriva Biologics Highlights Key Achievements in Q3 2024
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe ongoing P2b VIRAGE study in pancreatic cancer evaluating VCN-01 + gemcitabine/nab-paclitaxel has completed enrollment and is expected to report top-line data, which could represent a key catalyst for Theriva.
Regulatory SupportThe oncolytic virus space has been gaining traction with investors and is poised for an active period, with Theriva's VCN-01 approach being differentiated and having orphan drug and fast track designations for pancreatic cancer.
Research And DevelopmentVCN-01 is being evaluated for the treatment of advanced retinoblastoma, showing promising results in reducing the number and size of vitreous seeds and resulting in complete tumor regression in some patients.
Bears Say
CommercializationThe commercialization timelines for VCN-01 have been extended to 2030, which has contributed to lowering the price target.
Financial PerformanceThe next capital raise for Theriva Biologics could be significantly dilutive given the challenging financing environment for biotech companies.
---
Ownership Overview
―
Insiders
0.49% Mutual Funds
<0.01% Other Institutional Investors
99.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TOVX FAQ
What was Theriva Biologics’s price range in the past 12 months?
Theriva Biologics lowest stock price was $1.03 and its highest was $12.28 in the past 12 months.
What is Theriva Biologics’s market cap?
Theriva Biologics’s market cap is $3.06M.
When is Theriva Biologics’s upcoming earnings report date?
Theriva Biologics’s upcoming earnings report date is May 13, 2025 which is in 41 days.
How were Theriva Biologics’s earnings last quarter?
Theriva Biologics released its earnings results on Mar 06, 2025. The company reported $6.03 earnings per share for the quarter, beating the consensus estimate of -$7.22 by $13.25.
Is Theriva Biologics overvalued?
According to Wall Street analysts Theriva Biologics’s price is currently Undervalued.
Does Theriva Biologics pay dividends?
Theriva Biologics does not currently pay dividends.
What is Theriva Biologics’s EPS estimate?
Theriva Biologics’s EPS estimate is -4.19.
How many shares outstanding does Theriva Biologics have?
Theriva Biologics has 2,782,449 shares outstanding.
What happened to Theriva Biologics’s price movement after its last earnings report?
Theriva Biologics reported an EPS of $6.03 in its last earnings report, beating expectations of -$7.22. Following the earnings report the stock price went down -4.255%.
Which hedge fund is a major shareholder of Theriva Biologics?
Currently, no hedge funds are holding shares in TOVX
---
Company Description
Theriva Biologics
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
---
TOVX Stock 12 Month Forecast
Average Price Target
$6.00
▲(435.71% Upside)
Technical Analysis
Titan Pharmaceuticals
―
Jaguar Animal Health
―
180 Life Sciences
―
NLS Pharmaceutics
―
SciSparc Ltd.
―
Best Analysts Covering TOVX
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-58.38%
reiterated a buy rating 22 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -58.38% per trade.
---